S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
BREAKING: Tiny biotech successfully treats blindness (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
BREAKING: Tiny biotech successfully treats blindness (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
BREAKING: Tiny biotech successfully treats blindness (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
BREAKING: Tiny biotech successfully treats blindness (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
BREAKING: Tiny biotech successfully treats blindness (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
BREAKING: Tiny biotech successfully treats blindness (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
BREAKING: Tiny biotech successfully treats blindness (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
BREAKING: Tiny biotech successfully treats blindness (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
NASDAQ:BPMC

Blueprint Medicines (BPMC) Stock Forecast, Price & News

$56.41
-1.34 (-2.32%)
(As of 05/30/2023 ET)
Compare
Today's Range
$56.05
$58.26
50-Day Range
$42.20
$58.50
52-Week Range
$37.82
$79.40
Volume
511,081 shs
Average Volume
564,929 shs
Market Capitalization
$3.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.84

Blueprint Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
29.1% Upside
$72.84 Price Target
Short Interest
Healthy
5.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Blueprint Medicines in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$1.27 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.55) to ($7.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

646th out of 1,009 stocks

Pharmaceutical Preparations Industry

323rd out of 494 stocks


BPMC stock logo

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Stock News Headlines

[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Save $200 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.
Analyst Expectations for Blueprint Medicines's Future
Blueprint Medicines (BPMC) Gets a Buy from JMP Securities
See More Headlines
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Company Calendar

Last Earnings
5/04/2023
Today
5/31/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPMC
Fax
N/A
Employees
495
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$72.84
High Stock Price Forecast
$114.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+29.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

Net Income
$-557,520,000.00
Net Margins
-284.02%
Pretax Margin
-281.29%

Debt

Sales & Book Value

Annual Sales
$204.04 million
Book Value
$8.60 per share

Miscellaneous

Free Float
58,399,000
Market Cap
$3.41 billion
Optionable
Optionable
Beta
0.72

Social Links


Key Executives

  • Kathryn HavilandKathryn Haviland
    President, Chief Executive Officer & Director
  • Christina RossiChristina Rossi
    Chief Operating Officer
  • Michael Landsittel
    Chief Financial Officer
  • Christopher K. Murray
    Senior Vice President-Technical Operations
  • Janet Loesberg
    Senior Vice President-Global Medical Affairs













BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 1 sell rating, 5 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPMC shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price forecast for 2023?

15 brokerages have issued 12-month target prices for Blueprint Medicines' shares. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they anticipate the company's share price to reach $72.84 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2023?

Blueprint Medicines' stock was trading at $43.81 at the beginning of 2023. Since then, BPMC stock has increased by 28.8% and is now trading at $56.41.
View the best growth stocks for 2023 here
.

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 3,580,000 shares, a decrease of 5.8% from the April 30th total of 3,800,000 shares. Based on an average daily trading volume, of 598,200 shares, the short-interest ratio is presently 6.0 days.
View Blueprint Medicines' Short Interest
.

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our BPMC earnings forecast
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) released its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($2.15) EPS for the quarter, beating analysts' consensus estimates of ($2.66) by $0.51. The biotechnology company earned $63.29 million during the quarter, compared to analysts' expectations of $41.85 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 100.31% and a negative net margin of 284.02%. The business's revenue for the quarter was up .9% on a year-over-year basis. During the same period last year, the business posted ($1.79) EPS.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.59%), BlackRock Inc. (10.95%), Wellington Management Group LLP (8.50%), Price T Rowe Associates Inc. MD (8.18%), State Street Corp (4.56%) and JPMorgan Chase & Co. (2.57%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Nicholas Lydon, Percy H Carter and Tracey L Mccain.
View institutional ownership trends
.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $56.41.

How much money does Blueprint Medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.41 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis.

How many employees does Blueprint Medicines have?

The company employs 495 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -